Eli Lilly and Company, the world's largest and oldest manufacturer of synthetic insulin, commanded the vast majority of the US insulin market, and Genentech knew that it stood little chance of competing with them, so the company decided to license its product to Eli Lilly. Within five years Genentech was collecting US $ 5 million in royalties on the license.
但基因科技深知自己絕對鬥不過寡占全美胰島素市場的禮來藥廠（Eli Lilly），它授權禮來生產代銷，5 年內淨賺 500 萬美元權利金（2 億台幣）。